Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

EU Debt Crisis Adds Uncertainty

The sovereign debt crisis in the EU could greatly change the landscape for contract services.
Jul 7, 2010

The sovereign debt crisis in the EU could greatly change the landscape for contract services.

Be Careful for What You Wish

Rising labor costs in China may result in increased competition for higher value services.
Jul 2, 2010

Rising labor costs in China may result in increased competition for higher value services.

Be Careful What You Wish For

Jul 1, 2010

Rising labour rates in China may reduce its cost advantage, but will probably result in western suppliers facing more competition for higher value services.

EU Debt Crisis Adds Uncertainty

The sovereign debt crisis in the EU could greatly change the landscape for contract services.
Jun 2, 2010

The sovereign debt crisis in the EU could greatly change the landscape for contract services.

EU debt crisis adds uncertainty for contract services

Having barely begun recovering from the economic slump that began in 2008, the contract services industry must now face the consequences of the debt crisis in Europe, which will include reduced bio/pharmaceutical expenditure by governments. CMOs will feel the effect of this in fewer batches and increased pressure to reduce prices.
Jun 1, 2010

Having barely begun recovering from the economic slump that began in 2008, the contract services industry must now face the consequences of the debt crisis in Europe, which will include reduced bio/pharmaceutical expenditure by governments.

The Lilly Way

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.
May 5, 2010

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

The Lilly Way

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.
May 2, 2010

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

The Lilly Way

Lilly faces up to the new realities of the bio/pharmaceutical industry by embracing outsourcing.
May 1, 2010

Lilly faces up to the new realities of the bio/pharmaceutical industry by embracing outsourcing.

Time for a Model Upgrade

CMOs' business model has all of the flaws of the captive model it is meant to replace.
Apr 7, 2010

CMOs' business model has all of the flaws of the captive model it is meant to replace.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here